logo
Vanqua Bio to Present at Upcoming Scientific Conferences

Vanqua Bio to Present at Upcoming Scientific Conferences

CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its lead clinical program, VQ-101, at two upcoming scientific conferences – the GBA1 Meeting 2025, which will take place in Montreal, Canada June 5-7, 2025 and the European Academy of Neurology, taking place in Helsinki, Finland June 21-24, 2025.
Vanqua Bio GBA1 Conference Presentation Information:
Title: VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase (GCase) Demonstrates Robust And Sustained Target Engagement In Humans
Session date and time: June 5th 11:00am EDT
Presenter: Dr. Dan Ysselstein, Head of Biology
Vanqua Bio EAN Conference ePresentation Information:
Title: The allosteric activator of glucocerebrosidase, VQ-101, shows sustained activation of lysosomal GCase in humans
Session date and time: June 23rd 2:30pm EEST
Presenter: Dr. Maurizio Facheris, CMO
About VQ-101
VQ-101 is a novel, orally administered, fully CNS-penetrant allosteric activator of glucocerebrosidase (GCase). VQ-101 is initially being investigated in GBA-Parkinson's (GBA-PD) and idiopathic Parkinson's disease (iPD). By restoring GCase activity to healthy levels, VQ-101 aims to address the underlying genetic mechanism of disease in GBA-PD and slow or stop the progression of disease. Initial Phase 1 results with VQ-101 demonstrated sustained lysosomal GCase activation in healthy volunteers by more than 75%. In preclinical studies in patient derived neurons, 50%+ GCase activation resulted in significant blockage of the accumulation of alpha synuclein, the pathogenic hallmark of PD. A Phase 1b study in patients with PD, with and without GBA mutations, is ongoing.
About Vanqua Bio
Founded in 2019 and headquartered in Chicago, Vanqua Bio is a biopharmaceutical company dedicated to discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenerative and inflammatory diseases. Our technology platform utilizes human genetics and patient-derived CNS cells to identify, validate, and clinically translate novel disease pathways associated with lysosomal dysfunction or aberrant activation of the innate immune system. Initially, we are targeting glucocerebrosidase (GCase) as a potential treatment for Parkinson's disease (PD). Additional programs address overactivation of the innate immune system in peripheral and central inflammatory disorders, including renal, dermatologic and neurodegenerative diseases. For more information, go to www.vanquabio.com.
[email protected]
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Business Wire

time8 minutes ago

  • Business Wire

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) ('Coya' or the 'Company'), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the publication of a new research study, partially funded by Coya. The study, led by Drs. Aaron Thome, a scientific advisor to Coya, and Stanley H. Appel, the chairperson of Coya's Scientific Advisory Board, explores the role of immune dysfunction in the pathogenesis of PD. It was published in the scientific journal Frontiers of Immunology, which can be accessed here. PD is one of the most prevalent neurodegenerative disorders, marked by the progressive loss of dopaminergic neurons in the substantia nigra. This degeneration leads to motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor symptoms, including cognitive impairment, autonomic dysfunction, and psychiatric disturbances. Peripheral immune dysfunction, characterized by altered cytokine levels and dysregulated immune cell function, appears to play a significant role in PD pathogenesis. Dr Stanley Appel, Director Johnston Center for Cellular Therapeutics at Houston Methodist Hospital commented: 'The data offer strong insights into how peripheral inflammation is a key driver of the pathophysiology of PD. During the early stages of disease, myeloid cells are anti-inflammatory, but in later stages there is increased oxidative stress and proinflammatory signaling that promote peripheral and CNS dysfunction. The observed correlation of peripheral monocytes with disease burden and progression further supports the proposed dual effect of COYA 302. This therapy is designed to both enhance the anti-inflammatory function of Tregs and suppress the inflammation caused by monocytes and macrophages.' 'Results of this novel research study confirm our findings in other serious neurodegenerative diseases driven by sustained inflammation and strengthen our multitargeted immunomodulatory approach as a strategy for treating severe conditions with high unmet needs' Dr Fred Grossman, Chief Medical Officer, added. Highlights of Study Results This cross-sectional study in peripheral blood monocytes isolated from patients with PD and age- and sex-matched controls showed differential expression of inflammatory, immunoregulatory, and chemotactic receptor transcripts, as summarized below: Upregulation of the pro-inflammatory cytokine interleukin 6 (IL-6) and interleukin 1 beta (IL-1b) transcripts was observed in PD monocytes compared to control monocytes, and its expression increased with advanced stages of PD. The chemokine receptor C-C receptor type 2 (CCR2), which facilitates monocyte migration to sites of inflammation, was upregulated in PD monocytes compared to controls. Additionally, CCR2 expression was increased in early PD and continued to rise with advancing disease stages. Transcripts of the mannose receptor (MRC1/CD206), a marker of alternatively activated (M2) myeloid cells, were upregulated in early-stage PD monocytes but declined with disease progression, resulting in decreased expression in late-stage disease. CD163, a scavenger receptor associated with immunoregulation and protection from oxidative stress, was increased in monocytes from PD patients. CD163 transcripts were low in early-stage PD but increased with disease progression. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A or PGC-1α), an important transcriptional activator, exhibited a slight but non-significant increase in early-stage PD monocytes. However, its transcript levels progressively declined as the disease advanced. Glutathione peroxidase 4 (GPX4), an antioxidant enzyme implicated in PD, was elevated in PD monocytes compared to controls. When stratified by disease stage, GPX4 expression increased early but declined in later stages of disease. Sirtuin 1 (SIRT1) and Sirtuin 3 (SIRT3) are NAD⁺-dependent deacetylases with critical roles in oxidative stress responses, mitochondrial regulation, and inflammation. SIRT1 transcripts were upregulated in PD monocytes relative to controls; expression increased during early and intermediate disease stages but declined with disease progression. Conversely, SIRT3 transcripts were reduced in PD monocytes, with early stage decreases that became more pronounced as disease advanced. About COYA 302 COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS. These mechanisms may have additive or synergistic effects. COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency. About Parkinson's Disease Parkinson's disease is a type of neurologic movement disorder, affecting the brain and causing difficulty with movements, or motor symptoms. It is characterized by its most common motor symptoms - tremors (a form of rhythmic shaking), stiffness or rigidity of the muscles, and slowness of movement (called bradykinesia) - but also manifests in non-motor symptoms including sleep problems, constipation, anxiety, depression, and fatigue, among others, which can be present well before any visible motor symptoms. It is a chronic and progressive condition, meaning that the symptoms become worse over time and can affect the ability to perform common daily activities. There are an estimated 1 million people in the U.S. living with Parkinson's disease and more than 10 million people worldwide. Most people who develop the symptoms of Parkinson's disease do so after the age of 50, but Parkinson's disease can affect younger persons as well. Approximately 10% of Parkinson's diagnoses occur before age 50. 1,2 1. National Institute of Neurological Disorders and Stroke website (accessed July 2025). 2. Parkinson's Foundation website (accessed July 2025). About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ('Tregs') to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. For more information about Coya, please visit Forward-Looking Statements This press release contains 'forward-looking' statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including information concerning our business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CIRA's Net Good Grants back Indigenous, rural and youth-led initiatives for a safer, more connected Canada
CIRA's Net Good Grants back Indigenous, rural and youth-led initiatives for a safer, more connected Canada

Hamilton Spectator

time14 minutes ago

  • Hamilton Spectator

CIRA's Net Good Grants back Indigenous, rural and youth-led initiatives for a safer, more connected Canada

OTTAWA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) — Today, CIRA is proud to announce 13 transformative, community-led initiatives funded through its 2025 Net Good Grants program. From remote broadband infrastructure to youth-focused cybersecurity training, these projects are advancing internet safety, access and digital sovereignty across Canada. Each initiative equips communities with the tools, knowledge and infrastructure they need to thrive in an increasingly challenging digital world. The collective impact spans most provinces and territories, reflecting a broad and diverse commitment to digital resilience from the ground up. Key insights In British Columbia, communities like rural Shuswap region and Cortes Island are developing locally governed broadband co-operatives so that they can build, own and operate networks to directly serve their residents and generate revenue. 'CIRA's support in advancing digital inclusion in the Shuswap will be crucial this year. The funding will empower our community to build open-access, community-driven internet solutions, attract new investment, and engage in inclusive national digital policy conversations. It opens new ways for local groups to address unique challenges and opportunities facing their underserved communities, such as access to online health, education and economic development through employment,' says Sue McCrae, President, Shuswap Economic Development Society. Initiatives like the Digital Defenders Project in Saskatchewan and the Northwest Territories, the SmartScroll Digital Safety Program in small-town Ontario and Cyber Ready Islanders in Prince Edward Island are helping young people recognize and respond to online harms, misinformation and privacy risks. 'We're proud to have been awarded this 2025 CIRA Net Good Grant! Through intergenerational collaboration, young people across the country will gain vital digital safety skills, support their peers through meaningful in-person dialogue and become part of a national network of youth leaders working to prevent grievances from hardening into violence and radicalization. This is a critical step toward a safe, more connected future,' says Sharif Mahdy, Chief Executive Officer, Students Commission of Canada For professional development, the University of Ottawa's CyberSafe Youth project is delivering cyber attack simulation training to youth in Quebec and Ontario, while the Malahat Nation in B.C. is establishing a cybersecurity operations centre and training hub through its Malahat Internet Safety Initiative. Every initiative is rooted in local collaboration, underscoring a community-first approach to digital empowerment. These projects not only focus on youth development, but will also train educators, parents and community leaders, extending their impact through intergenerational learning and institutional partnerships. Whether through civic engagement in internet policy, broadband infrastructure co-ops, or multilingual online safety programs, these projects exemplify how community-led innovation can drive systemic change and ensure no one is left behind in Canada's digital future. Executive quote 'These projects are powerful examples of how communities across Canada are taking charge of their digital futures. By investing in local infrastructure, online safety and policy engagement, we are helping Canadians build the resilience they need to navigate digital threats, overcome connectivity challenges and shape a more equitable internet on their own terms.'— Charles Noir, Vice-president, Community Investment, Policy & Advocacy, CIRA Actua The organization will enhance its Cyber Smart Program to equip 5,000 young Canadians with essential cyber safety and digital literacy skills. Prioritizing equity-deserving communities, this project will deliver interactive, hands-on programs led by post-secondary student instructors. Participants will learn to critically analyze online information, combat cyber bullying, and become responsible digital citizens, fostering a safer and more informed online experience. Assembly of First Nations (National Indian Brotherhood) This initiative will assess Canada's spectrum ownership, licensing and policy decisions to develop recommendations that support First Nations' access to spectrum. The findings will inform national policy and strengthen First Nations' capacity for spectrum advocacy. By advancing digital sovereignty and enabling participation in telecommunications, the initiative will help close the connectivity gap and empower First Nations to shape their digital futures. A.S.T.C. Science World Society The organization aims to equip students and educators across British Columbia with the skills to use AI tools safely and responsibly. They will deliver workshops and online resources that promote digital literacy and critical thinking, with a focus on identifying and avoiding online misinformation. Community Resource Centre (Killaloe) Inc. CRC's Digital Safety Program will deliver an eight-session digital safety program to youth in grades 3–8 across rural Renfrew County, equipping them with essential digital literacy and online safety skills. Through interactive workshops and family engagement materials, participants will learn about cyberbullying, privacy and responsible digital behavior. Kijicho Manito Madaouskarini The program will deliver culturally grounded AI and cybersecurity education to 10 Algonquin communities through classroom toolkits and digital resources. It will empower over 1,000 Indigenous youth, educators and leaders with the skills to navigate digital environments safely, contribute to AI policy development, and pursue technology careers, as well as foster long-term digital resilience through open-source, curriculum-aligned learning and community-led governance. Malahat Nation A new Cybersecurity Operations Centre & Training Hub will deliver hands-on learning and certification, strengthening digital sovereignty and building long-term community resilience. This project will empower Malahat Nation community members and staff to manage their digital environments securely through culturally relevant cybersecurity training, infrastructure and mentorship. Shuswap Economic Development Society The initiative will develop a comprehensive technical and financial planning package to support the deployment of a community-owned fibre broadband network in the Shuswap region. It will include network designs, cost-benefit analyses and implementation schedules to connect 1,702 underserved households across 16 rural, remote and Indigenous communities. The initiative will lay the groundwork for affordable, high-speed internet access and long-term digital inclusion through a locally governed co-op model. STEAM PEI Ltd The Cyber Ready Islanders project will equip P.E.I. students, educators and guardians with the tools and confidence to navigate online spaces safely. Through workshops, camps and family events, participants will learn to recognize and respond to cyber threats and cyberbullying, supported by hands-on experiences and accessible resources. The initiative will foster a stronger digital safety network across schools, homes and communities in both English and French-speaking regions. Students Commission of Canada The SCC will engage youth and the adults who support them in co-creating and delivering activities that prevent online violence and reduce the risk of radicalization. Through workshops in Northern Saskatchewan and the Northwest Territories, participants will explore critical topics such as grooming, gender-based violence and extremist content, while building early intervention skills. Université de Montréal This initiative will strengthen the capacity of French-speaking post-secondary students and civil society to engage with the legal, technological and political dimensions of digital sovereignty. Through workshops, a summer school, ambassador training and public media campaigns, it will foster informed civic participation and leadership in internet governance. University of Ottawa Engineering Outreach The program will train 3,700 youth in cybersecurity and online safety through immersive, hands-on learning experiences. High school students will complete a certification program featuring a cyber attack simulation and practical training in digital defence, while elementary students will engage in interactive workshops tailored to their level. Vancouver Internet Exchange This project will establish a regional Internet Exchange in the Thompson-Okanagan region to improve local connectivity, reduce internet costs and enhance digital resilience across the Okanagan region. By interconnecting ISPs, content providers and network operators, the exchange will serve over 235,000 people, including rural, Indigenous and student populations. The initiative will also expand the Vancouver Internet Exchange's (VANIX) reach and support long-term regional digital growth and innovation. Resources About CIRA CIRA is the national not-for-profit best known for managing the .CA domain on behalf of all Canadians. As a leader in Canada's internet ecosystem, CIRA offers a wide range of products, programs and services designed to make the internet a secure and accessible space for all. CIRA advocates for Canada on both national and international stages to support its goal of building a trusted internet for Canadians by helping shape the future of the internet. About Net Good by CIRA and Net Good Grants Net Good by CIRA is how CIRA gives back to Canada's internet. Funded from the revenue generated through .CA domains, the program supports communities, projects and policies that make Canada's internet a better place. Grants are one of Net Good's most valuable contributions, with over $14 million invested in hundreds of community-led internet projects across the country that address infrastructure, online safety and policy engagement needs. Media contact Delphine Avomo Evouna 613.315.1458 A photo accompanying this announcement is available at

Talisker Receives Assay Results from 1105 Level Lateral Development at the Mustang Mine
Talisker Receives Assay Results from 1105 Level Lateral Development at the Mustang Mine

Hamilton Spectator

timean hour ago

  • Hamilton Spectator

Talisker Receives Assay Results from 1105 Level Lateral Development at the Mustang Mine

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) — Talisker Resources Ltd. ('Talisker' or the 'Company') (TSX: TSK, OTCQX: TSKFF) is pleased to announce that the Company has received assay results from underground face sampling of lateral development from the 1105 level at the Mustang Mine. Lateral development is mining conducted along the vein to allow for equipment access required for later stope extraction between levels. This development is conducted at approximately 3 X 3 metre dimensions, larger than the 1.8 metre width of the actual mining stopes. The 1105 level is located 1,105 metres above mean sea level and represents one of the upper most levels of the Mustang Mine. Sampling on this level was conducted to support future stopes identified on the Alhambra, BK and BK9870 veins. Sampling is conducted by cutting a linear horizontal channel approximately 10 centimeters wide across the width of the development face. Key Highlights: Terry Harbort, CEO of Talisker stated, 'These outstanding results from the 1105 level face sampling reinforce the high-grade nature of Bralorne and its position as one of the world's highest grade gold deposits. Even diluted to development widths of 3 metres, which is well beyond our mining width of 1.8 metres we see strong confirmation of the consistent grade with abundant occurrences of visible gold (shown in the face photos below in green). Shareholders will also note, the close correlation between our modelled veins displayed by the blue and red lines and the actual vein position. An excellent outcome for our dedicated resource modelling team!' Talisker is actively milling run of mine gold bearing development material at Nicola Mining's Merrit mill facility. To date, a total of 2,143 tonnes of material has been milled producing approximately 12 kilograms of gravity concentrate and 40 tonnes of sulphide concentrate. A further 2,200 tonnes of material has been delivered to the mill and is awaiting milling. The first sale and shipment of concentrate material is expected at the end of this month. Talisker is continuing to deliver new run of mine material daily at a rate of approximately 150 tpd. A Media Snippet accompanying this announcement is available by clicking on this link. For further information, please contact: Terry Harbort President and CEO +1 416 357 0227 Qualified Person The technical information contained in this news release relating to the drill results at the Bralorne Gold Project has been approved by Leonardo de Souza (BSc, AusIMM (CP) Membership 224827), Talisker's Vice President, Exploration and Resource Development, who is a 'qualified person' within the meaning of National Instrument 43-101, Standards of Disclosure for Mineral Projects. About Talisker Resources Ltd. Talisker ( is a junior resource company involved in the exploration and development of gold projects in British Columbia, Canada. Talisker's flagship asset is the high-grade, fully permitted Bralorne Gold Project where the Company is currently transitioning into underground production at the Mustang Mine. Talisker projects also include the Ladner Gold Project, an advanced stage project with significant exploration potential from an historical high-grade producing gold mine and the Spences Bridge Project where the Company holds ~85% of the emerging Spences Bridge Gold Belt, and several other early-stage Greenfields projects. Sample Preparation and QAQC Drill core at the Bralorne Gold Project is drilled in HQ to NQ size ranges (63.5mm and 47.6mm, respectively). Drill core samples are a minimum of 50 cm and a maximum of 160 cm long along the core axis. Samples are focused on an interval of interest, such as a vein or zone of mineralization. Shoulder samples bracket the interval of interest such that a total sampled core length of not less than 3m both above and below the interval of interest must be assigned. Sample QAQC measures of unmarked certified reference materials (CRMs), blanks, and duplicates are inserted into the sample sequence and makeup 9% of the samples submitted to the lab for holes reported in this release. ALS Global performs sample preparation and analyses in North Vancouver, British Columbia, Canada and SGS Canada in Burnaby, British Columbia, Canada. Drill core sample preparation includes drying in an oven at a maximum temperature of 60°C, fine crushing of the sample to at least 70% passing less than 2 mm, sample splitting using a riffle splitter, and pulverizing a 250 g split to at least 85% passing 75 microns (ALS code PREP-31 / SGS code PRP89). Gold in diamond drill core is analyzed by fire assay and atomic absorption spectroscopy (AAS) of a 50g sample (ALS code Au-AA26 / SGS code GO_FAA50V10), while multi-element chemistry is analyzed by 4- Acid digestion of a 0.25 g sample split with detection by inductively coupled plasma mass spectrometer (ICP-MS) for 48 elements (Ag, Al, As, Ba, Be, Bi, Ca, Cd, Ce, Co, Cr, Cs, Cu, Fe, Ga, Ge, Hf, In, K, La, Li, Mg, Mn, Mo, Na, Nb, Ni, P, Pb, Rb, Re, S, Sb, Sc, Se, Sn, Sr, Ta, Te, Th, Ti, Tl, U, V, W, Y, Zn, Zr). Gold assay technique (ALS code Au-AA26 / SGS code FAA50V10) has an upper detection limit of 100 ppm. Any sample that produces an over-limit gold value via the gold assay technique is sent for gravimetric finish (ALS method Au-GRA22 / SGS method GO_FAG50V) which has an upper detection limit of 1,000 ppm Au. Samples where visible gold was observed are sent directly to screen metallics analysis and all samples that fire assay above 1 ppm Au are re-analyzed with method (ALS code Au-SCR24 / SGS code - 6 - GO_FAS50M) which employs a 1kg pulp screened to 100 microns with assay of the entire oversize fraction and duplicate 50g assays on the undersize fraction. Where possible all samples initially sent to screen metallics processing will also be re-run through the fire assay with gravimetric finish provided there is enough material left for further processing. Caution Regarding Forward Looking Statements Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Talisker's current belief or assumptions as to the outcome and timing of such future events. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Talisker. Although such statements are based on reasonable assumptions of Talisker's management, there can be no assurance that any conclusions or forecasts will prove to be accurate. Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined, risks relating to variations in grade or recovery rates, risks relating to changes in mineral prices and the worldwide demand for and supply of minerals, risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks regulatory risks, including risks relating to the acquisition of the necessary licenses and permits, financing, capitalization and liquidity risks, title and environmental risks and risks relating to the failure to receive all requisite shareholder and regulatory approvals. The forward-looking information contained in this release is made as of the date hereof, and Talisker is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store